0001104659-23-084965.txt : 20230728
0001104659-23-084965.hdr.sgml : 20230728
20230728060820
ACCESSION NUMBER: 0001104659-23-084965
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230727
FILED AS OF DATE: 20230728
DATE AS OF CHANGE: 20230728
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kim Na Yeon
CENTRAL INDEX KEY: 0001794779
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37809
FILM NUMBER: 231120080
MAIL ADDRESS:
STREET 1: C/O NEUROBO PHARMACEUTICALS, INC.
STREET 2: 177 HUNTINGTON AVENUE, SUITE 1700
CITY: BOSTON
STATE: MA
ZIP: 02115
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NeuroBo Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001638287
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 472389984
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 BERKELEY ST.
STREET 2: FL 19
CITY: BOSTON
STATE: MA
ZIP: 02116
BUSINESS PHONE: (857) 702-9600
MAIL ADDRESS:
STREET 1: 200 BERKELEY ST.
STREET 2: FL 19
CITY: BOSTON
STATE: MA
ZIP: 02116
FORMER COMPANY:
FORMER CONFORMED NAME: Gemphire Therapeutics Inc.
DATE OF NAME CHANGE: 20150331
4
1
tm2321997-6_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2023-07-27
0
0001638287
NeuroBo Pharmaceuticals, Inc.
NRBO
0001794779
Kim Na Yeon
C/O NEUROBO PHARMACEUTICALS, INC.
200 BERKELEY STREET, OFFICE 19TH FLOOR
BOSTON
MA
02116
1
0
1
0
0
Common Stock
2023-07-27
4
A
0
87500
0
A
88959
D
Common Stock
2023-07-27
4
A
0
12500
0
A
101459
D
Common Stock
4671
I
Held by E&Investment Inc.
Common Stock
96351
I
Held by The E&Healthcare Investment Fund II
Common Stock
37373
I
Held by The E&Healthcare Investment Fund No. 6
Common Stock
62159
I
Held by The E&Healthcare Investment Fund No. 7
Represents a grant of restricted stock units ("RSUs") issued to the reporting person under the Issuer's 2022 Equity Incentive Plan.
50% of the RSUs vested immediately, and the remainder will vest in two equal installments on each subsequent anniversary of the date of grant, subject to continuing service.
The share amount has been adjusted to reflect the reverse stock split effective on September 12, 2022 whereby each thirty shares issued and outstanding prior to the split were combined and converted into one share of common stock.
Vests on the earlier of July 27, 2024 or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to continuing service.
Ms. Kim is the Chief Executive Officer of E&Investment, Inc., which is the sole general partner of The E&Healthcare Investment Fund II, The E&Healthcare Investment Fund No. 6 and The E&Investment Healthcare Fund No. 7, and as such, has voting and investment control over the shares held by E&Investment and its affiliated funds. The reporting person disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interest therein.
/s/ Phillip D. Torrence, by Power of Attorney
2023-07-28